Entity

Adverse Drug Event Record

The documented occurrence of a medication-related adverse event including suspected drug, reaction type, severity, and causality assessment.

Last updated: February 2026Data current as of: February 2026

Why This Object Matters for AI

AI ADE detection requires historical event data to learn patterns; without ADE records, AI cannot identify medication combinations or patient factors causing harm.

Quality & Patient Safety Capacity Profile

Typical CMC levels for quality & patient safety in Healthcare organizations.

Formality
L3
Capture
L3
Structure
L2
Accessibility
L2
Maintenance
L2
Integration
L2

CMC Dimension Scenarios

What each CMC level looks like specifically for Adverse Drug Event Record. Baseline level is highlighted.

L0

Adverse drug events are not formally documented. When a patient has a bad reaction to a medication, the clinical team addresses it in the moment but nobody files a formal record. The reaction may be noted in a progress note, but there is no structured ADE documentation. The organization cannot answer 'how many ADEs did we have last quarter?' because the events are not formally captured.

None — AI cannot detect ADE patterns, predict medication-related harm, or identify high-risk drug combinations because no formal adverse drug event records exist.

Implement formal ADE documentation — create a standardized adverse drug event reporting form that captures the suspected medication, reaction type, severity classification, onset timing, and patient outcome for every medication-related adverse event.

L1

Adverse drug events are reported through an incident reporting system, but documentation quality varies. Some reports provide detailed information about the suspected drug, reaction, and timeline. Others are brief narrative descriptions that omit critical details like dosage, route, onset timing, or severity. The event is documented but the level of clinical detail depends on who completes the report.

AI can count reported ADEs and identify the most frequently reported medication classes, but cannot perform rigorous causality analysis or detect subtle patterns because the clinical details documented in each report vary significantly in completeness.

Standardize ADE documentation — require every report to capture structured fields for suspected medication (with dose, route, frequency), reaction description (using MedDRA terminology), severity grade (using CTCAE or equivalent), onset timing, contributing factors, and patient outcome.

L2

Adverse drug events follow standardized documentation with all required clinical fields. Each ADE record captures the suspected medication with dose and route, the reaction using coded terminology (MedDRA), severity grade, onset timing relative to drug administration, contributing patient factors, actions taken, and patient outcome. The pharmacy team can consistently classify and analyze ADEs across the organization. But ADE records are standalone reports — they are not linked to the patient's complete medication history, lab values, or allergy profile.

AI can categorize ADEs consistently, identify the most common drug-reaction pairs, and track ADE frequency trends. Cannot correlate events with the patient's full medication regimen, renal function, drug interactions, or genetic factors because the ADE record is disconnected from the broader clinical profile.

Link ADE records to clinical context — connect each adverse event to the patient's complete medication administration record, relevant lab values (renal function, hepatic function, drug levels), documented allergies, and pharmacogenomic profile when available.

L3Current Baseline

ADE records are linked to the patient's broader clinical context. Each event connects to the complete medication administration record (all concurrent medications), relevant lab values (creatinine, liver enzymes, drug levels), documented allergy history, and the clinical timeline showing when each medication was started, adjusted, or discontinued. A pharmacist can query 'show me this patient's ADE timeline correlated with renal function decline and all concurrent medications with known interactions.'

AI can perform sophisticated causality analysis — evaluating drug-drug interactions, dose-response relationships, organ function changes, and temporal patterns to assess ADE likelihood. Can identify patients at elevated risk based on their current medication regimen and clinical profile.

Implement formal ADE entity schemas — model each event as a structured entity with typed relationships to medication orders, administration records, lab results, patient characteristics, clinical outcomes, and regulatory reporting submissions.

L4

ADE records are schema-driven entities with full relational modeling. Each event links to suspected and concomitant medication orders, administration timestamps, pre-event and post-event lab values, patient demographics and genetic markers, clinical interventions and outcomes, and regulatory reporting records (FDA MedWatch). An AI agent can navigate the complete ADE context from drug administration through reaction to outcome and reporting.

AI can autonomously manage ADE surveillance — monitoring every medication administration for interaction risks, correlating with patient-specific factors, detecting potential ADEs from clinical signal patterns, and generating causality assessments for pharmacovigilance review.

Implement real-time ADE event streaming — publish every medication administration, lab result, vital sign change, and clinical observation as it occurs, enabling continuous ADE signal detection rather than retrospective reporting.

L5

ADE records are part of a real-time pharmacovigilance intelligence stream. Every medication administration, lab result, vital sign change, and clinical observation that could signal a drug reaction is processed in real-time. ADE detection is not dependent on someone filing a report — the system continuously monitors for drug reaction signals and generates ADE assessments as clinical events unfold.

Can autonomously operate real-time pharmacovigilance — detecting potential ADEs from streaming clinical signals, assessing causality in real-time, alerting clinical teams, and generating regulatory reports as a continuous medication safety intelligence engine.

Ceiling of the CMC framework for this dimension.

Capabilities That Depend on Adverse Drug Event Record

Other Objects in Quality & Patient Safety

Related business objects in the same function area.

What Can Your Organization Deploy?

Enter your context profile or request an assessment to see which capabilities your infrastructure supports.